StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)

Equities research analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Stock Performance

Shares of NASDAQ DRRX opened at $0.77 on Thursday. DURECT has a fifty-two week low of $0.68 and a fifty-two week high of $1.88. The company has a market cap of $23.75 million, a price-to-earnings ratio of -1.25 and a beta of 0.94. The business’s 50 day moving average price is $0.85 and its 200-day moving average price is $1.19.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC grew its position in DURECT Co. (NASDAQ:DRRX) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 319,905 shares of the specialty pharmaceutical company’s stock after buying an additional 14,658 shares during the quarter. Geode Capital Management LLC owned 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. Institutional investors own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.